retatrutide phase 2 trial type 2 diabetes weight loss 2024 Lilly's triple agonist delivers up to 71.2 lbs of Advancements in Clinical Research and

Sources Eli Lilly press release TRIUMPH-1 Phase 3 topline results, May 21, 2026 Eli Lilly press release TRIUMPH-4 Phase 3 trial results, December 2025 Eli Lilly press release TRANSCEND-T2D-1 topline results, March 19, 2026 Bajaj HS et al

A standard therapeutic dose designed to make sedentary patients eat dramatically less would have turned every long session into a fueling crisis

Speak to your GP about referral and eligibility

If you need help navigating this transition or want to explore whether compounded options might keep you on tirzepatide affordably, TrimRx offers telehealth consultations with providers who manage these decisions regularly

Are they effective for prediabetes

Microdosing means using well-below-standard starting doses of a GLP1 agonist to gain metabolic and neurologic benefits while minimizing side effects